Leerink Swann Lowers Adaptimmune Therapeutics (ADAP) to Market Perform

Leerink Swann cut shares of Adaptimmune Therapeutics (NASDAQ:ADAP) from an outperform rating to a market perform rating in a report published on Tuesday morning, The Fly reports. The brokerage currently has $4.15 price objective on the biotechnology company’s stock.

Other equities analysts have also issued reports about the stock. Zacks Investment Research raised shares of Adaptimmune Therapeutics from a hold rating to a buy rating and set a $6.00 price objective for the company in a research report on Wednesday, February 13th. BidaskClub raised shares of Adaptimmune Therapeutics from a strong sell rating to a sell rating in a research report on Monday, April 1st. Two analysts have rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the company’s stock. The company has a consensus rating of Hold and a consensus target price of $6.53.

ADAP stock opened at $4.22 on Tuesday. Adaptimmune Therapeutics has a one year low of $3.55 and a one year high of $14.54. The company has a current ratio of 8.55, a quick ratio of 9.46 and a debt-to-equity ratio of 0.12.

Adaptimmune Therapeutics (NASDAQ:ADAP) last released its quarterly earnings results on Monday, May 6th. The biotechnology company reported ($0.24) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.28) by $0.04. Adaptimmune Therapeutics had a negative net margin of 161.09% and a negative return on equity of 45.03%. Sell-side analysts expect that Adaptimmune Therapeutics will post -1.21 EPS for the current fiscal year.

Several institutional investors have recently made changes to their positions in the stock. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its position in shares of Adaptimmune Therapeutics by 8.7% in the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 28,621 shares of the biotechnology company’s stock valued at $123,000 after purchasing an additional 2,280 shares during the last quarter. Raymond James & Associates raised its position in Adaptimmune Therapeutics by 31.8% during the 1st quarter. Raymond James & Associates now owns 30,185 shares of the biotechnology company’s stock worth $130,000 after buying an additional 7,279 shares during the last quarter. BlackRock Inc. raised its position in Adaptimmune Therapeutics by 1.6% during the 3rd quarter. BlackRock Inc. now owns 775,405 shares of the biotechnology company’s stock worth $10,514,000 after buying an additional 12,113 shares during the last quarter. SG Americas Securities LLC raised its position in Adaptimmune Therapeutics by 157.3% during the 4th quarter. SG Americas Securities LLC now owns 20,004 shares of the biotechnology company’s stock worth $115,000 after buying an additional 12,229 shares during the last quarter. Finally, Virtus ETF Advisers LLC raised its position in Adaptimmune Therapeutics by 54.8% during the 4th quarter. Virtus ETF Advisers LLC now owns 58,223 shares of the biotechnology company’s stock worth $335,000 after buying an additional 20,620 shares during the last quarter. 65.96% of the stock is owned by hedge funds and other institutional investors.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. Its platform enables in identifying cancer targets; finding and genetically engineering T-cell receptors (TCR); and producing TCR therapeutic candidates for administration to patients.

Read More: Trade Deficit

The Fly

Analyst Recommendations for Adaptimmune Therapeutics (NASDAQ:ADAP)

Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.